Quoin Pharmaceuticals, Ltd.

QNRX

NASDAQ

Healthcare

Biotechnology

Ashburn, VA, US3 employeesquoinpharma.com

$6.96

+0.90(14.85%)

Mkt Cap $4M

$5.28

$22.30

52-Week Range

At a Glance

AI-generated

Quoin Pharmaceuticals, Ltd.

8-K

Quoin Pharmaceuticals Ltd. announced Q4 and full-year 2025 financial results with net loss of $4.3 million and $15.8 million respectively, cash position of $18.7 million funding into 2027, closed $104.5 million private placement financing, and key regulatory progress for QRX003 including Orphan Drug and Fast Track Designations for Netherton Syndrome.

$4M

Market Cap

—

Revenue

-$14M

Net Income

Employees3

Fundamentals

How The Business Makes Money

Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.

Industry Biotechnology

Activity

What Changed Recently

Financial Results

Mar 25, 2026

shall not be deemed to be “filed” with the Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the

Regulation FD

Mar 10, 2026

and Exhibit 99.1 attached hereto are furnished and shall not be deemed to be “filed” with the Securities and Exchange Commission (the “SEC”) for purposes of Sec

Regulation FD

Jan 19, 2026

and Exhibit 99.1 attached hereto are furnished and shall not be deemed to be “filed” with the Securities and Exchange Commission (the “SEC”) for purposes of Sec

Company Profile

CIK0001671502

ISINUS74907L4095

CUSIP74907L409

Phone703 980 4182

Address42127 Pleasant Forest Court, Ashburn, VA, 20148-7349, US

SEC EDGAR